Influence of strain on anisotropic thermoelectric transport of Bi2_2Te3_3 and Sb2_2Te3_3

On the basis of detailed first-principles calculations and semi-classical Boltzmann transport, the anisotropic thermoelectric transport properties of Bi$_2$Te$_3$ and Sb$_2$Te$_3$ under strain were investigated. It was found that due to compensation effects of the strain dependent thermopower and electrical conductivity, the related powerfactor will decrease under applied in-plane strain for Bi$_2$Te$_3, while being stable for Sb$_2$Te$_3$. A clear preference for thermoelectric transport under hole-doping, as well as for the in-plane transport direction was found for both tellurides. In contrast to the electrical conductivity anisotropy, the anisotropy of the thermopower was almost robust under applied strain. The assumption of an anisotropic relaxation time for Bi$_2$Te$_3$ suggests, that already in the single crystalline system strong anisotropic scattering effects should play a role

Bi2Te3Bi_2Te_3: Implications of the rhombohedral k-space texture on the evaluation of the in-plane/out-of-plane conductivity anisotropy

Different computational scheme for calculating surface integrals in anisotropic Brillouin zones are compared. The example of the transport distribution function (plasma frequency) of the thermoelectric Material \BiTe near the band edges will be discussed. The layered structure of the material together with the rhombohedral symmetry causes a strong anisotropy of the transport distribution function for the directions in the basal (in-plane) and perpendicular to the basal plane (out-of-plane). It is shown that a thorough reciprocal space integration is necessary to reproduce the in-plane/out-of-plane anisotropy. A quantitative comparison can be made at the band edges, where the transport anisotropy is given in terms of the anisotropic mass tensor.Comment: 7 pages, 6 figs., subm. to J. Phys. Cond. Ma

Thermoelectric transport in Bi2Te3/Sb2Te3\text{Bi}_2\text{Te}_3/\text{Sb}_2\text{Te}_3 superlattices

The thermoelectric transport properties of $\text{Bi}_2\text{Te}_3/\text{Sb}_2\text{Te}_3$superlattices are analyzed on the basis of first-principles calculations and semi-classical Boltzmann theory. The anisotropy of the thermoelectric transport under electron and hole-doping was studied in detail for different superlattice periods at changing temperature and charge carrier concentrations. A clear preference for thermoelectric transport under hole-doping, as well as for the in-plane transport direction was found for all superlattice periods. At hole-doping the electrical transport anisotropies remain bulk-like for all investigated systems, while under electron-doping quantum confinement leads to strong suppression of the cross-plane thermoelectric transport at several superlattice periods. In addition, insights on the Lorenz function, the electronic contribution to the thermal conductivity and the resulting figure of merit are given

The landmarks of control and licensing system development for medicinal products in Russia (25 years since the establishment of the first state institution for expert evaluation of medicinal products)

The article describes the landmarks of control and licensing system development for the purpose of drug evaluation, marketing authorization and circulation in Russia. The need for the development of a state institution for performing expert evaluation of medicines was satisfied in 1990 by the establishment of the All-Soviet Union Scientific Centre for Expert Evaluation of Medicines (renamed in 1992 as the Russian State Centre for Expert Evaluation of Medicines - RSCEEM). The activities of the Centre included expert evaluation of all documents for new pharmaceutical products; organization and monitoring of clinical trials, as well as the assessment of their results; development of the recommendations regarding marketing authorization and medical use of new medicines. It also exercised the functions of the Federal Centre for Adverse Drug Reaction Study. RSCEEM became a basis for modern currently functioning Scientific Centre for Expert Evaluation of Medicinal Products»

История создания и развития контрольно-разрешительной системы лекарственных средств в России (25 лет со времени создания первого государственного учреждения по экспертной оценке лекарственных средств)

The article describes the landmarks of control and licensing system development for the purpose of drug evaluation, marketing authorization and circulation in Russia. The need for the development of a state institution for performing expert evaluation of medicines was satisfied in 1990 by the establishment of the All-Soviet Union Scientific Centre for Expert Evaluation of Medicines (renamed in 1992 as the Russian State Centre for Expert Evaluation of Medicines - RSCEEM). The activities of the Centre included expert evaluation of all documents for new pharmaceutical products; organization and monitoring of clinical trials, as well as the assessment of their results; development of the recommendations regarding marketing authorization and medical use of new medicines. It also exercised the functions of the Federal Centre for Adverse Drug Reaction Study. RSCEEM became a basis for modern currently functioning Scientific Centre for Expert Evaluation of Medicinal Products».В статье представлена история создания и развития контрольно-разрешительной системы оценки, регистрации и обращения лекарственных средств. Необходимость создания для этих целей специального государственного учреждения была реализована организацией в 1990 году Всесоюзного научного центра экспертизы лекарственных средств (в 1992 году переименованного в Российский государственный центр экспертизы лекарств). Этот центр обеспечивал экспертную оценку материалов на новые лекарственные препараты, организовывал и мониторировал клинические испытания, рассматривал их результаты, готовил рекомендации по регистрации и медицинскому применению новых лекарств, а также выполнял функции Федерального центра по изучению побочных действий лекарственных средств. Российский государственный центр экспертизы лекарств явился основой функционирующего в настоящее время ФГБУ «Научный центр экспертизы средств медицинского применения»